Download PDF
Dtsch Med Wochenschr 2001; 126(Suppl. Gastroenterol. 1): S68-S75
DOI: 10.1055/s-2001-14495
Supplement Gastroenterologie (1)
© Georg Thieme Verlag Stuttgart · New York

PEG-Interferone: Bedeutung für die Therapie der Virushepatitis B und C

PEG-interferons: significance for the treatment of viral hepatitis B and CH. Wedemeyer, M. Cornberg, M. P. Manns
  • Abteilung Gastroenterologie und Hepatologie (Direktor: Prof. Dr. med. M.P. Manns) der Medizinischen Hochschule Hannover
Further Information

Publication History

Publication Date:
11 September 2002 (online)

Also available at
   Permissions and Reprints
Preview

Weltweit leiden mehr als eine halbe Milliarde Menschen unter einer chronischen Infektion mit einem Hepatitisvirus. Während von ca. 170 Millionen Patienten mit chronischer Hepatitis C ausgegangen wird, sind etwa 350 Millionen Menschen chronische Träger des Hepatitis-B-Virus. Die virale Hepatitis ist die Hauptursache für Leberzellkrebs und Lebertransplantationen in der westlichen Welt. Die Therapie der chronischen Hepatitis C und B hat sich in den letzten Jahren deutlich weiterentwickelt, die Einführung von pegylierten Interferonen stellt hierbei die jüngste Neuerung dar.

Literatur

  • 1 EASL International Consensus Conference on hepatitis C. Paris, 26 - 27 February 1999. Consensus statement.  J Hepatol. 1999;  31 3-8 (Suppl 1))
    Search in Google Scholar
  • 2 Bailon P, Palleroni A, Schaffer C A, Spence C L, Fung W J, Porter J E. et al . Rational Design of a Potent, Long-Lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-Conjugated Interferon alpha-2a for the Treatment of Hepatitis C.  Bioconjug Chem. 2001;  12 195-202
    Search in Google Scholar
  • 3 Boker K H, Manns M P. Therapy of chronic viral hepatitis.  Internist. 1999;  40 1275-1287
    Search in Google Scholar
  • 4 Carithers R L, Zeuzem S, Manns M P, McHutchison J, Perrillo R P, Bailey R. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin.  Hepatology. 2000;  32 631A
    Search in Google Scholar
  • 5 Cheng S J, Bonis P A, Lau J, Pham N Q, Wong J B. Interferon and ribavirin for patients with chronic hepatitis C who did not respond to previous interferon therapy: A meta-analysis of controlled and uncontrolled trials.  Hepatology. 2001;  33 231-240
    Search in Google Scholar
  • 6 Glue P, Fang J W, Rouzier-Panis R, Raffanel C, Sabo R, Gupta S K. et al . Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.  Clin Pharmacol Ther. 2000;  68 556-567
    Search in Google Scholar
  • 7 Glue P, Rouzier-Panis R, Raffanel C, Sabo R, Gupta S K, Salfi M. et al . A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.  Hepatology. 2000;  32 647-653
    Search in Google Scholar
  • 8 Heathcote E J, Shiffman M L, Cooksley W G, Dusheiko G M, Lee S S, Balart L. et al . Peginterferon Alfa-2a in Patients with Chronic Hepatitis C and Cirrhosis.  N Engl J Med. 2000;  343 1673-1680
    Search in Google Scholar
  • 9 Heathcote E J, Shiffman M L, Pockros P J, Lee S S, Reddy K R, Minuk G. et al . Pegylated (40KDA) interferon alfa-2a (PEGASYSä) is superior to interferon alfa-2a (ROFERON-A) in improving posttreatment histologic outcome in chronic hepatitis C patients 1584.  Hepatology. 2000;  32 223A
    Search in Google Scholar
  • 10 Hoofnagle J H, Lau D, Conjeevaram H, Kleiner D, Di Bisceglie A M. Prolonged therapy of chronic hepatitis C with ribavirin.  J Viral Hepat. 1996;  3 247-252
    Search in Google Scholar
  • 11 Hopf U, Niederau C, Kleber G, Fleig W E. The treatment of chronic viral hepatitis B/D and acute and chronic viral hepatitis C. The consensus of the German Society for Digestive and Metabolic Diseases.  Z Gastroenterol. 1997;  35 971-986
    Search in Google Scholar
  • 12 Jaeckel E, Cornberg M, Mayer J, Koerbel J N, Wedemeyer H, Schuler A. et al . Early treatment of acute hepatitis C infection with intreferon-alpha 2b monotherapy prevents development of chronic HCV infection.  Hepatology. 2000;  32 318A
    Search in Google Scholar
  • 13 Jaeckel E, Manns M P. The course and therapy of acute hepatitis C viral infection. Is a prevention of its becoming chronic possible.  Z Gastroenterol. 2000;  38 387-395
    Search in Google Scholar
  • 14 Janssen H L, Brouwer J T, van der Mast R C, Schalm S W. Suicide associated with alfa-interferon therapy for chronic viral hepatitis.  J Hepatol. 1994;  21 241-243
    Search in Google Scholar
  • 15 Kallinowski B, Liehr H, Moeller B, Stremmel W, Wechsler J G, Wiese M. et al . Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.  Z Gastroenterol. 2001;  39 199-204, 206
    Search in Google Scholar
  • 16 Lam N P, Neumann A U, Gretch D R, Wiley T E, Perelson A S, Layden T J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.  Hepatology. 1997;  26 226-231
    Search in Google Scholar
  • 17 Manns M, McHutchison J G, Gordorn S, Rustgi V, Lee M V, Ling M L. et al . Pegylated interferon alpha 2b (PEG IFN) plus ribavirin (R) for treatment of chronic hepatitis C: Optimization of ribavirin dose.  J.Hepatol. 2001;  34 236
    Search in Google Scholar
  • 18 Manns M P, McHutchison J, Gordon S C, Rustgi V K, Shiffman M L, Lee W. et al . Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial.  Hepatology. 2000;  32 297A
    Search in Google Scholar
  • 19 Martin P, Mardip S, Martin N E, Nutley N J. Pegylated (40KDA) interferon alfa-2a (PEGASYS™) is unaffected by renal impairment.  Hepatology. 2000;  32 370A
    Search in Google Scholar
  • 20 McHutchison J G, Gordon S C, Schiff E R, Shiffman M L, Lee W M, Rustgi V K. et al . Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.  N Engl J Med. 1998;  339 1485-1492
    Search in Google Scholar
  • 21 Modi M W, Fulton J S, Wright T L, Moore D J. Clearance of Pegylated (40KDA) Interferon alfa-2a (PEGASYS) is primarily hepatic.  Hepatology (Abstract). 2000;  32 371A
    Search in Google Scholar
  • 22 Modi M W, Nutley N J, Fried M, Rustgi V K, Raymond K, Wright T. et al . The pharmacokinetic behavior of pegylated (40KDA) interferon alfa-2a (PEGASYS™) in chronic hepatitis C patients after multiple dosing.  Hepatology (Abstract). 2000;  32 394A
    Search in Google Scholar
  • 23 Musselman D L, Lawson D H, Gumnick J F, Manatunga A K, Penna S, Goodkin R S. et al . Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 961-966
    Search in Google Scholar
  • 24 Neumann A U, Lam N P, Dahari H, Gretch D R, Wiley T E, Layden T J. et al . Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.  Science. 1998;  282 103-107
    Search in Google Scholar
  • 25 Nieforth K A, Nadeau R, Patel I H, Mould D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.  Clin Pharmacol Ther. 1996;  59 636-646
    Search in Google Scholar
  • 26 Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E. et al . Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response.  J Immunol. 1998;  160 3487-3493
    Search in Google Scholar
  • 27 Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S. et al . Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.  Lancet. 1995;  346 1051-1055
    Search in Google Scholar
  • 28 Nishiguchi S, Shiomi S, Nakatani S, Takeda T, Fukuda K, Tamori A. et al . Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.  Lancet. 2001;  357 196-197
    Search in Google Scholar
  • 29 Okuda K. Hepatocellular carcinoma.  J Hepatol. 2000;  32 225-237 (Suppl 1))
    Search in Google Scholar
  • 30 Pockros P J, Heathcote E J, Shiffman M L, Bain V, Zeuzem S, Manns M P. et al . Efficacy of pegylated (40KDA) interferon alfa-2a (PEGASYS™) in randomized trials of patients with chronic hepatitis C, with and without cirrhosis: correlation of virologic responses with baseline liver histology and genotype.  Hepatology. 2000;  32 442A
    Search in Google Scholar
  • 31 Poynard T, Marcellin P, Lee S S, Niederau C, Minuk G S, Ideo G. et al. International Hepatitis Interventional Therapy Group (IHIT) . Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus.  Lancet. 1998;  352 1426-1432
    Search in Google Scholar
  • 32 Poynard T, McHutchison J, Goodman Z, Ling M H, Albrecht J. The ALGOVIRC Project Group . Is an »a la carte« combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C.  Hepatology. 2000;  31 211-218
    Search in Google Scholar
  • 33 Reddy K R, Wright T L, Pockros P J, Shiffman M, Everson G, Reindollar R. et al . Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.  Hepatology. 2001;  33 433-438
    Search in Google Scholar
  • 34 Schalm S W, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B. et al . Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial.  Gut. 2000;  46 562-568
    Search in Google Scholar
  • 35 Shiffman M L, Hofmann C M, Contos M J, Luketic V A, Sanyal A J, Sterling R K. et al . A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia.  Gastroenterology. 1999;  117 1164-1172
    Search in Google Scholar
  • 36 Terrault N A. Combined interferon and lamivudine therapy: is this the treatment of choice for patients with chronic hepatitis B virus infection?.  Hepatology. 2000;  32 675-677
    Search in Google Scholar
  • 37 Trepo C, Lindsay K, Niederau C, Shiffman M, Gordon S C, Hoefs J. Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C.  J Hepatol. 2000;  32 29
    Search in Google Scholar
  • 38 Valla D C, Chevallier M, Marcellin P, Payen J L, Trepo C, Fonck M. et al . Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.  Hepatology. 1999;  29 1870-1875
    Search in Google Scholar
  • 39 Wedemeyer H, Caselmann W H, Manns M P. Combination therapy of chronic hepatitis C: an important step but not the final goal!.  J Hepatol. 1998;  29 1010-1014
    Search in Google Scholar
  • 40 Wedemeyer H, Jackel E, Wedemeyer J, Frank H, Schuler A, Trautwein C. et al . Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated? - An analysis of personal experiences and review of the literature.  Z Gastroenterol. 1998;  36 819-827
    Search in Google Scholar
  • 41 Zeuzem S, Feinman S V, Rasenack J, Heathcote E J, Lai M Y, Gane E. et al . Peginterferon Alfa-2a in Patients with Chronic Hepatitis C.  N Engl J Med. 2000;  343 1666-1672
    Search in Google Scholar

Korrespondenz

Dr. med. Heiner Wedemeyer

Abteilung Gastroenterologie und Hepatologie Medizinische Hochschule Hannover

Carl Neuberg Straße 1

30625 Hannover

Phone: 0511/532 2853

Fax: 0511/532 2093

Email: h_wedemeyer@yahoo.com